MIDATECH PHARMA
Technologies | Nano-Inclusion Technology

Nano-Inclusion Technology

Midatech has applied its know-how in the formation of stable and water-soluble nanoscale complexes of otherwise low-aqueous-solubility small-molecule drugs.  Such complexes have particular application in the local delivery of cancer therapeutics for treatment of brain cancers for poorly soluble and poorly brain-penetrant drugs.  They are particularly stable and can produce millimolar concentrations of drug at biological pH.  Studies to date show no reduction in efficacy for the complexes.  Production at scale is feasible and product can be stored freeze-dried with a long shelf-life.   

Midatech’s lead program using this technology is MTX110, a highly water-soluble formulation of panobinostat for CED (Convection Enhanced Delivery), that is in clinical development for treatment of DIPG, a rare and fatal childhood brain cancer.

Technologies
Nano-Inclusion Technology

Nano-Inclusion Technology

Midatech has applied its know-how in the formation of stable and water-soluble nanoscale complexes of otherwise low-aqueous-solubility small-molecule drugs.  Such complexes have particular application in the local delivery of cancer therapeutics for treatment of brain cancers for poorly soluble and poorly brain-penetrant drugs.  They are particularly stable and can produce millimolar concentrations of drug at biological pH.  Studies to date show no reduction in efficacy for the complexes.  Production at scale is feasible and product can be stored freeze-dried with a long shelf-life.   

Midatech’s lead program using this technology is MTX110, a highly water-soluble formulation of panobinostat for CED (Convection Enhanced Delivery), that is in clinical development for treatment of DIPG, a rare and fatal childhood brain cancer.

© Copyright 2018 Midatech Pharma PLC